Are antifungal non-inferiority trials at risk of eroding effectiveness because of bio-creep? A secondary analysis of a systematic review,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Are antifungal non-inferiority trials at risk of eroding effectiveness because of bio-creep? A secondary analysis of a systematic review
Antimicrobial Agents and Chemotherapy ( IF 4.9 ) Pub Date : 2021-10-18 , DOI: 10.1128/aac.01627-21
Adam S Komorowski _{1,

2} , Anthony D Bai _{2,

3} , Anna Cvetkovic ₄ , Omar Mourad ₄ , Carson K L Lo ₄ , Xena X Li _{1,

4} , Vaibhav Mokashi ₄ , Aidan Findlater ₄ , D Brody Duncan ₁ , Charlotte Fuller ₁ , Daniela L Leto _{1,

4} , Deborah Yamamura _{1,

4} , Dominik Mertz ₄ ,

Affiliation

Non-inferiority randomized controlled trial (RCT) effectiveness may erode when results favour the active control over time, and when a decreasingly effective control arm is used in serial trials. We analyzed 32 antifungal noninferiority RCTs (NI-RCTs) for ...

中文翻译：